Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Christoph Huwe

Ulrich Lücking

Rolf Jautelat

Olaf Prien

Gerhard Siemeister

Martina Schäfer

Thomas Brumby

Ulrich Klar

Wolfgang Schwede

Arwed Cleve

Andrea Rotgeri

Wilhelm Bone

Jens Hoffmann

Carsten Möller

Gary Bruce Phillips

Gerhard Sauer

Hans Briem

Brad Owen Buckman

Dirk Kosemund

Knut Eis

Joachim Kuhnke

Benjamin Bader

Martin Schneider

Shendong Yuan

Monica J Kochanny

Volker Schulze

Damian O Arnaiz

Judith Günther

Stuart Ince

Richard L Feldman

Peter Esperling

Karsten Parczyk

Lars Wortmann

Judi Bryant

Dieter Zopf

Seock-Kyu Khim

Andreas Reichel

Manfred Husemann

Ulrich Zügel

Karina Schuck

Ulf Bomer

Emil Eckle

Helmut Morack

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyomata), endometriosis, heavy menstrual bleeding, meningiomata, hormone-dependent breast cancers and menopause-associated complaints or for fertility control and emergency contraception.

Progesterone receptor antagonists

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of the formula I with a progesterone antagonizing effect and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and also their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular of uterus fibroids (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeding, meningiomas, hormone-dependent breast cancers and troubles associated with the menopause or for monitoring fertility and emergency contraception.

The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.

Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments

This invention relates to pyrimidine derivatives of general formula I in which R, R, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents

This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

This invention relates to pyrimidine derivatives of general formula Iin which R, R, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

Compound and a composition including such a compound

This invention relates to new piperazine derivatives of general formula I,in which V, W, n, R, R', i, j, Y and Z have the meaning that is indicated in the description. The compounds according to the invention are distinguished by a diazacycloalkane substituent. They have at their disposal a special action with respect to the action that destabilizes the androgen receptor and can be used, for example, for treating prostrate cancer.

Piperazine derivatives that destabilize androgen receptors

The invention relates to new 7&agr;, 17&agr;, 17&bgr;-substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-term antiandrogen therapy of prostate carcinoma. In the general formula (I) A is an unbranched C -C -alkylene group; B is an oxygen atom, &mdash;S(O) &mdash; group, in which p is 0, 1 or 2, an iminocarbonyl group &mdash;C(O)N(Y)&mdash;, an imino group &mdash;N(Y)&mdash;, a carbonylimino group &mdash;N(Y)C(O)&mdash;, a sulfonylimino group &mdash;NN(Y)S(O) &mdash;, where Y is a hydrogen atom or a C -C -alkyl group, a sulfonyloxy group &mdash;OS(O) &mdash;, a dimethylsilyloxy group &mdash;O&mdash;Si(CH ) &mdash; or a carbonylsulfanyl group &mdash;SC(O)&mdash; or a bond between A and C or, together with C, a bond between A and D; C is a bond between B and D or, together with B, a bond between A and D or an unbranched C -C -alkylene group, a phenylene group, a substituted phenylene group, a five-membered ring or six-membered ring heteroarylene group, a substituted five-membered ring or six-membered ring heteroarylene group or a five-membered ring or six-membered ring heteroarylene group fused with a phenyl ring; and D is a hydrogen atom, a C -C -alkyl group, a vinyl group, a C -C -alkoxy group, a C -C -alkoxycarbonyl group, a bis(C -C -alkoxycarbonyl)methyl group, an acetyl(C -C -alkoxybonyl)methyl group, a cyan group, a carboxy group, an azide group, a hydroxy group, a halogen atom or a rest of the formula C F H , in which n is 1, 2, 3 or 4, m>1 and m&plus;o&equals;2n&plus;1.

New7&agr;, 17&agr;-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases

Growing community of inventors

Berlin, Germany

Christoph Huwe